心钠肽(ANP)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Atrial Natriuretic Peptide (ANP)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
- 编号CEA225Mu
- 物种Mus musculus (Mouse，小鼠)相同的名称，不同的物种。
- 实验方法竞争抑制
- 反应时长2h
- 检测范围12.35-1,000pg/mL
- 灵敏度最小可检测剂量小于等于4.74pg/mL.
- 样本类型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载英文说明书 中文说明书
- 规格48T96T96T*596T*1096T*100
- 价格¥ 2722¥ 3888¥ 17496¥ 33048¥ 272160
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
特异性
本试剂盒用于检测心钠肽(ANP)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的心钠肽(ANP)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 90-101 | 93 |
| EDTA plasma(n=5) | 82-89 | 85 |
| heparin plasma(n=5) | 90-104 | 94 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的心钠肽(ANP)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中心钠肽(ANP)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-105% | 93-102% | 82-99% | 80-91% |
| EDTA plasma(n=5) | 86-93% | 81-90% | 86-93% | 78-90% |
| heparin plasma(n=5) | 81-94% | 99-105% | 78-91% | 79-97% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）50µL，
加入50µL检测液A(临用前配制);
37°C温育1小时。
3. 洗板3次；
4. 加检测溶液B100µL，37°C孵育30分钟；
5. 洗板5次；
6. 加TMB底物90µL，37°C孵育10-20分钟；
7. 加终止液50µL，立即450nm读数。
实验原理
本试剂盒应用竞争抑制酶联免疫分析法测定标本中待测物质水平。将心钠肽(ANP)单克隆抗体包被微孔板，制成固相载体，往包被抗体的微孔中同时加入生物素标记的抗原和待测抗原(标准品或样本)，待测抗原与生物素标记抗原对特异性抗体进行竞争结合。温育后经洗涤去掉未结合物，然后加入HRP标记的亲和素，经过温育和彻底洗涤后加入底物TMB显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。待测标本浓度越高，标记抗原和抗体的结合就越受到抑制，显色愈浅。显色的深浅与酶量呈正相关，而与样品中待测物质含量呈负相关。用酶标仪在450nm波长下测定吸光度（O.D.值），计算样品浓度。
相关产品
| 编号 | 适用物种：Mus musculus (Mouse，小鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA225Mu02 | 心钠肽(ANP)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA225Mu01 | 心钠肽(ANP)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA225Mu02 | 心钠肽(ANP)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA225Mu01 | 心钠肽(ANP)多克隆抗体 | WB; IHC; ICC; IP. |
| LAA225Mu71 | 心钠肽(ANP)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| SEA225Mu | 心钠肽(ANP)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA225Mu | 心钠肽(ANP)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| MEA225Mu | 心钠肽(ANP)检测试剂盒(酶联免疫吸附试验法,小样本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA225Mu | 心钠肽(ANP)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
| KSA225Mu11 | 心钠肽(ANP)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
| 杂志 | 参考文献 |
| 8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function[PubMed: 21616283] |
| Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery[PubMed: 21769675] |
| Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients[PubMed: 23406607] |
| European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment.[Pubmed: 24356727] |
| Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx[Pubmed:25497357] |
| Diabet Med. | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.[Pubmed:26927445] |
| J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway[Pubmed:26970569] |
| Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease.[papers:uobj_paper_2016_62613672.pdf] |
| PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy[pubmed:29240788] |
| Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.[pubmed:29063791] |
| Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation[Pubmed:29504933] |
| Science of the Total Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and[Pubmed:29727991] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice[Pubmed:29929978] |
| Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease[Pubmed:29392348] |
| FASEB Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure[Pubmed: 30230922] |
| Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension …[Pubmed: 30359461] |
| International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma[] |
| Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure.[] |
| Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy[34094834] |
| Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy[34624429] |
| Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress[Pubmed:35218795] |
